The Latin America, Middle East and Africa Gastroesophageal Reflux Disease Therapeutics Market would witness market growth of 5.1% CAGR during the forecast period (2022-2028).
Acid contact with the esophageal mucosa still plays a significant role in developing symptoms and the induction of inflammatory lesions at the distal part of the esophagus. Hence, it is not unexpected that the primary medical strategy for treating GERD patients focuses on reducing acid output.
Because they bind to the H+K+ ATP-ase, which is the last step in the production of acid by the gastric parietal cell, proton pump inhibitors (PPIs) are the most potent antisecretory medications currently on the market. As a result, they have quickly replaced the less potent H2-receptor antagonists (H2RAs) as the first-choice medications for controlling this important element in the pathogenesis of GERD. PPIs have more antisecretory action than H2RAs, although their effectiveness varies depending on how much the clinical signs and symptoms of the condition are caused by acid.
The EE type of GERD is one of the most responsive, especially when it manifests with more severe mucosal damage, which falls between B and D of the well-known Los Angeles classification. Several randomized clinical studies, systematic reviews, and meta-analyses have shown that PPIs have a very high healing rate in these individuals. When PPIs are compared to placebo and H2RAs, their efficiency in treating esophageal mucosal changes is linked with a speedy remission of typical illness symptoms, notably heartburn.
In Israel, the proportion of adults and kids who are overweight or obese has increased. According to the KAP study from 2008, obesity affects 13.7%, and overweight affects 34% of adults over 18. An imbalance between the number of calories ingested and the energy lost during physical exercise leads to weight increase and, ultimately, obesity. Excess calories are typically consumed through high-calorie fast food, expanding portion sizes, and the low cost of high-calorie food. At the same time, physical activity has decreased due to the increased time people spend watching television, using computers, and using other electronic devices. The increasing obesity for various reasons is expected to surge the number of patients with digestive tract complications and boost the market's expansion in the region in LAMEA.
The Brazil market dominated the LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $99 Million by 2028. The Argentina market is experiencing a CAGR of 5.7% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 4.8% during (2022 - 2028).
Based on Type, the market is segmented into Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Gastroesophageal Reflux Disease Therapeutics Market is Projected to reach USD 5.6 Billion by 2028, at a CAGR of 2.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).
By Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 